The stem cell therapy market is expected to grow at a CAGR of 12.1% during the projected period. The market value is expected to increase from US$ 16.7 billion in 2024 to US$ 52.1 billion by 2034.
Attributes | Details |
---|---|
Stem Cell Therapy Market Size, 2024 | US$ 16.7 billion |
Projected Market Size, 2034 | US$ 52.1 billion |
Value-based CAGR (2024 to 2034) | 12.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Attributes | Details |
---|---|
Top Therapy | Autologous Cellular Immunotherapies |
CAGR (2024 to 2034) | 11.8% |
Attributes | Details |
---|---|
Top Source | Bone Marrow |
CAGR (2024 to 2034) | 11.6% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Countries | CAGR through 2034 |
---|---|
United States | 12.3% |
United Kingdom | 13.3% |
China | 12.8% |
Japan | 13.7% |
South Korea | 14.0% |
The market is highly competitive due to the presence of several leading pharmaceutical and biotech companies. It is characterized by intense competition, rapid technological advancements, and a high degree of research and development activities aimed at developing innovative stem cell therapies. Companies are investing heavily in research and development initiatives aimed at developing novel stem cell therapies for a range of medical conditions.
Recent Development in the Stem Cell Therapy Market
In 2020, Cipla and Stempeutics formed a strategic collaboration to introduce Stempucel, a groundbreaking stem cell therapy for the treatment of critical limb ischemia. The collaboration is aimed at capitalizing on the growing demand for stem cell therapies and expanding their market share in this rapidly evolving field. The launch of Stempucel is expected to revolutionize the treatment of critical limb ischemia, a debilitating condition that affects millions of people worldwide.
The market is estimated to be valued at US$ 16.7 billion in 2024.
The market in China is expected to progress at a CAGR of 12.8% through the forecast period.
Within the therapy, the autologous cellular immunotherapies segment is expected to register an 11.8% CAGR from 2024 to 2034
The United States market is expected to rise at a 12.3% CAGR from 2024 to 2034.
The market is set to reach a valuation of US$ 52.1 billion by 2034.
The demand for stem cell therapies increased at a 15.6% CAGR from 2019 to 2023.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2024 to 2034
5.3.1. Autologous Cellular Immunotherapies
5.3.2. Autologous Stem Cell Therapy
5.4. Y-o-Y Growth Trend Analysis By Therapy, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Therapy, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Source
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Source, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Source, 2024 to 2034
6.3.1. Bone Marrow
6.3.2. Epidermis
6.3.3. Mesenchymal Stem Cells
6.3.4. Other Sources
6.4. Y-o-Y Growth Trend Analysis By Source, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Source, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034
7.3.1. Cancer
7.3.2. Cardiovascular Disorders
7.3.3. Neurodegenerative Disorders
7.3.4. Orthopedics
7.3.5. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-Use
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-Use, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-Use, 2024 to 2034
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Surgical Centers
8.3.3. Research Centers
8.3.4. Other End-Users
8.4. Y-o-Y Growth Trend Analysis By End-Use, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By End-Use, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Therapy
10.2.3. By Source
10.2.4. By Application
10.2.5. By End-Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Therapy
10.3.3. By Source
10.3.4. By Application
10.3.5. By End-Use
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Therapy
11.2.3. By Source
11.2.4. By Application
11.2.5. By End-Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Therapy
11.3.3. By Source
11.3.4. By Application
11.3.5. By End-Use
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Therapy
12.2.3. By Source
12.2.4. By Application
12.2.5. By End-Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Therapy
12.3.3. By Source
12.3.4. By Application
12.3.5. By End-Use
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Therapy
13.2.3. By Source
13.2.4. By Application
13.2.5. By End-Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Therapy
13.3.3. By Source
13.3.4. By Application
13.3.5. By End-Use
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Therapy
14.2.3. By Source
14.2.4. By Application
14.2.5. By End-Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Therapy
14.3.3. By Source
14.3.4. By Application
14.3.5. By End-Use
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Therapy
15.2.3. By Source
15.2.4. By Application
15.2.5. By End-Use
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Therapy
15.3.3. By Source
15.3.4. By Application
15.3.5. By End-Use
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Therapy
16.2.3. By Source
16.2.4. By Application
16.2.5. By End-Use
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Therapy
16.3.3. By Source
16.3.4. By Application
16.3.5. By End-Use
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Market Share Analysis, 2023
17.1.1.1. By Therapy
17.1.1.2. By Source
17.1.1.3. By Application
17.1.1.4. By End-Use
17.2. Canada
17.2.1. Market Share Analysis, 2023
17.2.1.1. By Therapy
17.2.1.2. By Source
17.2.1.3. By Application
17.2.1.4. By End-Use
17.3. Brazil
17.3.1. Market Share Analysis, 2023
17.3.1.1. By Therapy
17.3.1.2. By Source
17.3.1.3. By Application
17.3.1.4. By End-Use
17.4. Mexico
17.4.1. Market Share Analysis, 2023
17.4.1.1. By Therapy
17.4.1.2. By Source
17.4.1.3. By Application
17.4.1.4. By End-Use
17.5. Germany
17.5.1. Market Share Analysis, 2023
17.5.1.1. By Therapy
17.5.1.2. By Source
17.5.1.3. By Application
17.5.1.4. By End-Use
17.6. UK
17.6.1. Market Share Analysis, 2023
17.6.1.1. By Therapy
17.6.1.2. By Source
17.6.1.3. By Application
17.6.1.4. By End-Use
17.7. France
17.7.1. Market Share Analysis, 2023
17.7.1.1. By Therapy
17.7.1.2. By Source
17.7.1.3. By Application
17.7.1.4. By End-Use
17.8. Spain
17.8.1. Market Share Analysis, 2023
17.8.1.1. By Therapy
17.8.1.2. By Source
17.8.1.3. By Application
17.8.1.4. By End-Use
17.9. Italy
17.9.1. Market Share Analysis, 2023
17.9.1.1. By Therapy
17.9.1.2. By Source
17.9.1.3. By Application
17.9.1.4. By End-Use
17.10. Poland
17.10.1. Market Share Analysis, 2023
17.10.1.1. By Therapy
17.10.1.2. By Source
17.10.1.3. By Application
17.10.1.4. By End-Use
17.11. Russia
17.11.1. Market Share Analysis, 2023
17.11.1.1. By Therapy
17.11.1.2. By Source
17.11.1.3. By Application
17.11.1.4. By End-Use
17.12. Czech Republic
17.12.1. Market Share Analysis, 2023
17.12.1.1. By Therapy
17.12.1.2. By Source
17.12.1.3. By Application
17.12.1.4. By End-Use
17.13. Romania
17.13.1. Market Share Analysis, 2023
17.13.1.1. By Therapy
17.13.1.2. By Source
17.13.1.3. By Application
17.13.1.4. By End-Use
17.14. India
17.14.1. Market Share Analysis, 2023
17.14.1.1. By Therapy
17.14.1.2. By Source
17.14.1.3. By Application
17.14.1.4. By End-Use
17.15. Bangladesh
17.15.1. Market Share Analysis, 2023
17.15.1.1. By Therapy
17.15.1.2. By Source
17.15.1.3. By Application
17.15.1.4. By End-Use
17.16. Australia
17.16.1. Market Share Analysis, 2023
17.16.1.1. By Therapy
17.16.1.2. By Source
17.16.1.3. By Application
17.16.1.4. By End-Use
17.17. New Zealand
17.17.1. Market Share Analysis, 2023
17.17.1.1. By Therapy
17.17.1.2. By Source
17.17.1.3. By Application
17.17.1.4. By End-Use
17.18. China
17.18.1. Market Share Analysis, 2023
17.18.1.1. By Therapy
17.18.1.2. By Source
17.18.1.3. By Application
17.18.1.4. By End-Use
17.19. Japan
17.19.1. Market Share Analysis, 2023
17.19.1.1. By Therapy
17.19.1.2. By Source
17.19.1.3. By Application
17.19.1.4. By End-Use
17.20. South Korea
17.20.1. Market Share Analysis, 2023
17.20.1.1. By Therapy
17.20.1.2. By Source
17.20.1.3. By Application
17.20.1.4. By End-Use
17.21. GCC Countries
17.21.1. Market Share Analysis, 2023
17.21.1.1. By Therapy
17.21.1.2. By Source
17.21.1.3. By Application
17.21.1.4. By End-Use
17.22. South Africa
17.22.1. Market Share Analysis, 2023
17.22.1.1. By Therapy
17.22.1.2. By Source
17.22.1.3. By Application
17.22.1.4. By End-Use
17.23. Israel
17.23.1. Market Share Analysis, 2023
17.23.1.1. By Therapy
17.23.1.2. By Source
17.23.1.3. By Application
17.23.1.4. By End-Use
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Therapy
18.3.3. By Source
18.3.4. By Application
18.3.5. By End-Use
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Lonza Group AG
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Novartis AG
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Bristol-Myers Squibb Company
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Corning Incorporated
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Holostem Terapie Avanzate S.r.l.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. CORESTEM, Inc
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Sanpower Group
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Tego Science
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Gilead Sciences
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Vericel Corporation
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports